Akums Launches Novel Formulations For Patients With Gastrointestinal Disorders

New Delhi: Akums Drugs & Pharmaceuticals Ltd on Monday announced that it has launched Rabeprazole + Levosulpiride SR Capsules. Approved by the Drug Controller General of India (DCGI), the company claims this new formulation aims to enhance relief for patients suffering from gastrointestinal tract (GIT) disorders.

GERD, or gastro-oesophageal reflux disease, is a debilitating condition characterised by the reflux of stomach contents into the oesophagus, leading to troublesome symptoms and potential complications. With GERD often dubbed as chronic acid reflux, its prolonged presence not only impacts the quality of life but also poses risks of serious health complications, including stomach and esophageal cancer.

“Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase at the surface of gastric parietal cells. It has demonstrated efficacy in treating gastric and duodenal ulcers, as well as GERD. Complementing rabeprazole, Levosulpiride, the levo-enantiomer of sulpiride, exhibits significant central antidopaminergic activity and antiemetic effects,” the company said in a statement.

Its peripheral anti-dopaminergic action modulates the motor activity of the upper digestive tract, making it valuable in gastro-enterology, it claimed.

“We are excited to introduce a solution for patients suffering from GERD and related gastrointestinal disorders. GERD diagnosis and treatment rely on symptom management and acid suppression therapies. Our Rabeprazole + Levosulpiride SR Capsules aim to offer an effective remedy, ease symptoms, enhance gastrointestinal function, and boost patients’ overall well-being. Levosulpiride offers rapid relief and better healing outcomes with fewer side effects, elevating the overall treatment experience,” Arushi Jain, Director, Akums Drugs & Pharmaceuticals Ltd. said in a statement.

Each hard gelatin capsule contains Rabeprazole Sodium IP 40 mg (as enteric-coated form) and Levosulpiride 75 mg (as uncoated sustained-release form). The recommended dosage is one capsule once daily or as directed by a physician.

Related Posts

ICMR mandates clinical trials to focus on Indian demography, lifestyle

New Delhi: Most medicines prescribed in India today are based on clinical trials conducted in Western countries. But Indian bodies, diets, and lifestyles are not the same. Prompted by this,…

India’s Medical Devices Market Is Set To Hit $50 Billion By 2030: Rubix Report

New Delhi:  India’s medical devices industry is on a remarkable growth trajectory, with projections indicating it will reach $50.1 billion by 2030, according to a recent report from Rubix Industry…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

ICMR mandates clinical trials to focus on Indian demography, lifestyle

ICMR mandates clinical trials to focus on Indian demography, lifestyle

India’s Medical Devices Market Is Set To Hit $50 Billion By 2030: Rubix Report

India’s Medical Devices Market Is Set To Hit $50 Billion By 2030: Rubix Report

Muradnagar Police Bust Fake Liver-52 DS Herbal Medicine Racket: Three Arrested

Muradnagar Police Bust Fake Liver-52 DS Herbal Medicine Racket: Three Arrested

Massive Eskuf haul seized from train in Agartala

Massive Eskuf haul seized from train in Agartala

Vadodara Police Seize Illegal Steroids and Testosterone Injections from Russia and Austria in Bodybuilding Shop Raid

Vadodara Police Seize Illegal Steroids and Testosterone Injections from Russia and Austria in Bodybuilding Shop Raid

35 drugs manufactured in Telangana fail CDSCO quality checks

35 drugs manufactured in Telangana fail CDSCO quality checks